Showing results (91-100 of 98) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 98 results.
Journal of Hematology & Oncology|February 24, 2017
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trialSrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Haematologica|January 25, 2015
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-ISrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
British Journal of Haematology|March 14, 2013
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosisSrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Haematologica|September 17, 2013
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-ISrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
The New England Journal of Medicine|March 2, 2012
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosisSrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Haematologica|November 2, 2023
ASXL1 mutations are associated with a response to alvocidib and 5-azacytidine combination in myelodysplastic neoplasmsVladimir Riabov, Qingyu Xu, Nanni Schmitt, et al.
Cancer Cell|March 28, 2025
A niche driven mechanism determines response and a mutation-independent therapeutic approach for myeloid malignanciesIoanna Mosialou, Abdullah M Ali, Rossella Labella, et al.
Haematologica|August 6, 2013
Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studiesRuben A Mesa, Jean-Jacques Kiladjian, Srdan Verstovsek, et al.
Pageof 10